Delivery Order SPE2DR25D3103-SPE2DR26F9J25
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,519.77 to AmerisourceBergen Drug Corp for Naloxone HCl 4 mg nasal spray (2-count units) on August 18, 2025, with completion targeted for August 19, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a single delivery order under AmerisourceBergen's larger pharmaceutical supply framework. Performance will be executed from the company's Conshohocken, Pennsylvania location,...
- The Defense Logistics Agency awarded a delivery order valued at $1,255.47 to AmerisourceBergen Drug Corp for Naloxone HCL 4 mg nasal spray (2-count units) on November 7, 2025, with completion targeted for November 10, 2025. This competitively awarded, firm fixed-price delivery order represents a small-value pharmaceutical procurement supporting federal medical supply needs. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,129.92 to AmerisourceBergen Drug Corp for the supply of Naloxone HCl 4 mg nasal spray on January 2, 2026, with an ultimate completion date of January 5, 2026. This firm fixed-price contract, issued without set-aside designation, represents a competitively awarded delivery order under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. The pharmaceutical will be delivered to...
- The Defense Logistics Agency awarded a $4,622.54 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Naloxone HCL 4 mg nasal spray on November 28, 2025, with an ultimate completion date of December 1, 2025. This award is a non-set-aside contract and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026....
- The Defense Logistics Agency awarded a delivery order valued at $10,266.71 to AmerisourceBergen Drug Corp for the supply of Naloxone HCl 4 mg nasal spray. This contract, which was competitively awarded with no set-aside designation, has a firm fixed price structure and an ultimate completion date of August 18, 2025. The product will be delivered to a location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Naloxone 4mg nasal spray (2-count units) under a firm fixed-price contract with a ceiling value of $1,206.15. The award, issued on December 18, 2025, with an ultimate completion date of December 19, 2025, represents a competitively awarded, non-set-aside transaction. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location. This order...
- The Defense Logistics Agency awarded a delivery order valued at $1,124.16 to AmerisourceBergen Drug Corp for Naloxone HCL 4 mg nasal spray (2-count units) on August 22, 2025, with completion scheduled for August 25, 2025. This firm fixed price contract was awarded competitively with no set-aside designation and is being performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,928.40 to AmerisourceBergen Drug Corp for Naloxone HCl 4 mg nasal spray (2-count units) on August 22, 2025, with an ultimate completion date of August 25, 2025. This firm fixed-price, non-set-aside contract is classified as a child award, indicating it derives from a larger contract vehicle. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $1,572.48 to AmerisourceBergen Drug Corp for Naloxone HCL 4 mg nasal spray (2-count units) on September 3, 2025, with an ultimate completion date of September 4, 2025. This firm fixed-price delivery order, issued without set-aside designation, represents a competitively awarded transaction under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (contract SPE2DX), valued at...
- The Defense Logistics Agency awarded a delivery order valued at $2,220.79 to AmerisourceBergen Drug Corp on December 11, 2025, for the supply of Naloxone HCL 4 mg nasal spray (2-spray units). The contract carries a firm fixed price and is scheduled for completion by December 12, 2025, with performance to take place at AmerisourceBergen's Conshohocken, Pennsylvania facility. This delivery order was competitively awarded with no set-aside designation, reflecting the vendor's established capability...
- SPE2DR25D3103Indefinite Delivery Contract
- SPE2DR25D3103-SPE2DR26F9J25Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,503.20 to AmerisourceBergen Drug Corp for Naloxone HCl 4 mg nasal spray on November 24, 2025, with completion scheduled for November 25, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitive award under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major pharmaceutical distributor serving federal medical procurement needs. This delivery order falls under AmerisourceBergen's existing $999,999,999 IDC with DLA Troop Support Medical (SPE2DX), which extends through December 2026 and serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. The naloxone delivery supports the Defense Health Agency's medical supply requirements and demonstrates the company's role as a critical vendor for pharmaceutical products across multiple therapeutic domains. AmerisourceBergen's federal contract portfolio reflects its established capability to fulfill competitive procurements ranging from small-value transactions to substantial orders, positioning the company as a key provider within DLA's pharmaceutical distribution network.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.5k | 11/23/25 |